Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (19087)	2/25/1999 2:26:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Vivus, The Research King In my coffee break I recorded the number of scientific papers 96-99 with the name of company in corporate address, and divided this by the market capitalization in billions to give a relative measure of scientific productivity. Scores below: This makes oral pill bedfellows of, Pfizer = 9 Zona = 9 And soon to be married, Zeneca = 37 Astra = 29 Exceeded by Bill Gates' sweetheart, Icos = 97 And the soon to be ED therapy King surging ahead, Vivus = 145 !! DaiS

To: VLAD who wrote (19087)	2/25/1999 3:41:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

More on short term trading of Vivus: If we close above 2 1/2 ish(I believe we will), then this old support level becomes our new support level. Our new resistance level becomes the same old same old as before in the 3 to 3 1/2ish range. If we can make a run through the 3's and close at or above 4 1/4 then there is resistance until the old support level of the 6's seen early last summer. A move up through 6 certainly will prove that we are on the way to recovery. In the short term without any news, I believe we will follow the old trading pattern between the 2 1/2 and 3 1/2 level so long as no more news comes out but I think we will continue getting bits and pieces of good news regarding further EU approvals and actual Astra launches. One ace in the hole is the promise behind the gene therapy research. So far Vivus has not produce one single press release informing the general public on Dr. Christ's research. Such releases would certainly get the general "herd" of mass speculators/momentum players back into buying Vivus. A well planned press release may not produce another Entremed run up (12 to 80 gap up) but it very well may be the necessary spark required to tell the investment community that the millions spent each quarter by Vivus are not being wasted and it may be the needed catalyst for a momentum booster to renew interest in Vivus.